<DOC>
	<DOCNO>NCT02945813</DOCNO>
	<brief_summary>The main objective trial determine SRT plus metformin superior SRT alone endpoint time progression prostatectomy failure .</brief_summary>
	<brief_title>PROMET - Trial Salvage Radiotherapy +/- Metformin Patients With Prostate Cancer After Prostatectomy</brief_title>
	<detailed_description>The use salvage radiotherapy biochemical progression prostatectomy provide suboptimal result year . Metformin show anti-cancer radio-sensitizing property several study , therefore promising drug improve treatment result important group patient . In trial , aim assess role metformin decrease failure ( PSA progression ) follow salvage radiotherapy . For , patient PSA progression surgery treat standard care ( salvage radiotherapy ) plus metformin .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Written inform consent accord ICH/GCP regulation registration prior trial specific procedure Histologically confirm adenocarcinoma prostate without small cell feature Tumor stage pT2a3b , pN0 cN0 , M0 , R01 resection margin , accord UICC TNM 2009 , Gleason score available Radical prostatectomy ( RP ) least 12 week registration PSA progression RP define two consecutive rise final PSA &gt; 0.1 ng/mL three consecutive rise . The first value must measure early 4 week RP PSA ≤ 2 ng/mL within 14 day prior registration Age ≥ 18 year time registration WHO performance status 01 Adequate hepatic function within 14 day prior registration : bilirubin ≤ 1.5 x ULN ( exception Gilbert 's syndrome ≤ 3 x ULN ) , AST ALT ≤ 2.5 x ULN Adequate renal function within 14 day prior registration : calculate correct creatinine clearance ≥ 60 mL/min , accord formula correct CockcroftGault Patient agree father child trial treatment 6 month thereafter Persistent PSA ( &gt; 0.4 ng/mL ) 4 20 week RP Pelvic lymph node enlargement &gt; 0.8 cm short axis diameter ( cN positive ) assess mpMRI within 12 week prior registration , unless enlarge lymph node sample negative Evidence macroscopic local recurrence assess mpMRI within 12 week prior registration Palpable prostatic fossa mass suggestive recurrence , unless ultrasound guide biopsy negative malignancy Presence history prostate cancer metastasis . In case clinical suspicion ( e.g . bone pain ) , image ( e.g . bone scan , CholinPET , PSMAPET , whole body MRI ) must perform . The image method discretion investigator . History hematologic primary solid tumor malignancy , unless remission least 3 year registration exception curatively treat localized nonmelanoma skin cancer Patients pharmacotherapy diabetes mellitus Treatment metformin within last 3 month prior registration Prior pelvic radiotherapy Hormonal treatment bilateral orchiectomy prior follow RP Usage product know affect PSA level within 4 week prior start trial treatment Bilateral hip prosthesis Severe active comorbidity likely impact advisability salvage RT , e.g . : History inflammatory bowel disease malabsorption syndrome condition would interfere enteral absorption Acute bacterial fungal infection require intravenous antibiotic time registration Unstable angina and/or congestive heart failure require hospitalization within last 6 month Transmural myocardial infarction within last 6 month Chronic Obstructive Pulmonary Disease ( COPD ) exacerbation respiratory illness require hospitalization preclude study therapy time registration Any condition associate increase risk lactic acidosis ( e.g . alcohol abuse , congestive heart failure NYHA III IV Clinically significant history liver disease consistent ChildPugh Class B C , include viral hepatitis , current alcohol abuse , cirrhosis Severe uncontrolled kidney disease result impaired kidney function ( GFR &lt; 60ml/min ) Any acute chronic condition could cause tissue hypoxia ( e.g . cardiac respiratory insufficiency , recent myocardial infarction , shock ) Treatment experimental drug participation within clinical trial within 30 day prior registration ( exception : concurrent participation biobank project SAKK 63/12 allow ) Any concomitant drug contraindicate use metformin accord approve product information Known hypersensitivity metformin/placebo component Hereditary intolerance fructose ; know galactose1phosphate uridyl transferase deficiency , UDP galactose 4 epimerase deficiency , galactokinase deficiency , FanconiBickel syndrome , congenital lactase deficiency , glucosegalactose malabsorption ( due lactosecontaining placebo ) Inability unwillingness swallow oral medication Any serious underlying medical , psychiatric , psychological , familial geographical condition , judgment investigator may interfere plan staging , treatment followup , affect patient compliance place patient high risk treatmentrelated complication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Prostate Cancer Prostatectomy</keyword>
	<keyword>Phase II Trial</keyword>
	<keyword>Salvage Radiotherapy</keyword>
	<keyword>Metformin</keyword>
</DOC>